-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, AstraZeneca announced that it has appointed Liu Ming as Vice President of AstraZeneca China, Head of the Lung Cancer Treatment and Tumor Immunotherapy-related Business Units of the Oncology Division, and joined the Chinese management team to directly report to AstraZeneca.
Chen Kangwei, general manager of Likang Oncology Division, reported that it will take effect on August 30
.
It is understood that before joining AstraZeneca, Liu Ming was the vice president of Novartis Oncology and the head of the solid tumor business unit, responsible for fields including breast cancer, lung cancer, melanoma, neuroendocrine tumors and rare diseases
.
It is worth noting that on June 9 this year, Zhu Jiakang, the former vice president of AstraZeneca China and the head of the lung cancer targeted therapy and tumor immunotherapy related fields, officially resigned
.
In July, Zhu Jiakang joined Novartis as the head of Novartis' innovative drug China oncology field and became a member of the innovative drug China management team
.
In fact, under the market changes, executive changes have long become the norm in the pharmaceutical industry
.
However, since this year, it can be clearly found that the changes of executives of pharmaceutical companies are more frequent
.
Taking Nova as an example, since the beginning of this year, in addition to frequent changes in executives, it has also announced more than one major layoffs
.
It is reported that in June, Novartis made a sensational announcement that it planned to lay off 8,000 employees, accounting for about 7% of the company's total workforce, in order to save at least $1 billion by 2024
.
Judging from the target of layoffs, Novartis has abolished a large number of executive positions this time, which shows that the adjustment of pharmaceutical companies behind it is accelerating
.
In addition to layoffs, Novartis' strategic restructuring plan includes the integration of its pharmaceutical and oncology business units
.
In the Chinese market, which it focuses on, it has previously merged the two business divisions of pharmaceuticals and oncology into one division
.
In addition to China, Novartis has also made frequent moves in other areas, which can be seen as a large-scale adjustment of the company
.
In addition to Novartis, AstraZeneca has had frequent executive departures since June last year
.
In this regard, industry analysts believe that it may be related to the failure of its blockbuster products in the respiratory field, budesonide inhalation and digestive system esomeprazole injection, to be successfully included in centralized procurement
.
At present, the whereabouts of most of these resigned executives have been confirmed.
Among them, He Yimin has joined Roche, and others have basically joined local innovative drug companies, such as Baiji and Luoxin
.
Incomplete statistics show that as of August this year, at least eight senior executives of the Chinese business departments of large multinational pharmaceutical companies have left their posts, with an average frequency of one a month; in terms of executives taking on new positions, there are a total of 24 personnel appointments
.
Of course, in addition to multinational companies, the executives of domestic pharmaceutical companies have also changed very frequently this year
.
Among them, it is worth noting that in the context of the departure of domestic and foreign pharmaceutical companies, the exchange of talents between multinational pharmaceutical companies and local innovative drug companies is becoming more and more frequent
.
For example, Liu Yan (Lily), vice president of BeiGene and head of marketing in Greater China, will resign.
According to industry sources, from July 1, he will join Genetron Health as Chief Commercial Officer (CCO) and will be fully responsible for the tumor diagnosis business.
;Jingyan Zhu, former head of the lymphoma business unit of Janssen's HIPO division, joined BeiGene as head of the hematology and oncology division; John P.
Gargiulo, president and CEO of Daiichi Sankyo North America, will join Ascletis after his departure Chief Commercial Officer.
.
.
From the above point of view, the transfer of talents between multinational pharmaceutical companies and domestic and foreign pharmaceutical companies has become the norm
.
The industry predicts that in the future, the flow of talents in the pharmaceutical arena will become more and more frequent, and the competition for talents between multinational pharmaceutical companies and local pharmaceutical companies will continue to intensify
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Chen Kangwei, general manager of Likang Oncology Division, reported that it will take effect on August 30
.
It is understood that before joining AstraZeneca, Liu Ming was the vice president of Novartis Oncology and the head of the solid tumor business unit, responsible for fields including breast cancer, lung cancer, melanoma, neuroendocrine tumors and rare diseases
.
It is worth noting that on June 9 this year, Zhu Jiakang, the former vice president of AstraZeneca China and the head of the lung cancer targeted therapy and tumor immunotherapy related fields, officially resigned
.
In July, Zhu Jiakang joined Novartis as the head of Novartis' innovative drug China oncology field and became a member of the innovative drug China management team
.
In fact, under the market changes, executive changes have long become the norm in the pharmaceutical industry
.
However, since this year, it can be clearly found that the changes of executives of pharmaceutical companies are more frequent
.
Taking Nova as an example, since the beginning of this year, in addition to frequent changes in executives, it has also announced more than one major layoffs
.
It is reported that in June, Novartis made a sensational announcement that it planned to lay off 8,000 employees, accounting for about 7% of the company's total workforce, in order to save at least $1 billion by 2024
.
Judging from the target of layoffs, Novartis has abolished a large number of executive positions this time, which shows that the adjustment of pharmaceutical companies behind it is accelerating
.
In addition to layoffs, Novartis' strategic restructuring plan includes the integration of its pharmaceutical and oncology business units
.
In the Chinese market, which it focuses on, it has previously merged the two business divisions of pharmaceuticals and oncology into one division
.
In addition to China, Novartis has also made frequent moves in other areas, which can be seen as a large-scale adjustment of the company
.
In addition to Novartis, AstraZeneca has had frequent executive departures since June last year
.
In this regard, industry analysts believe that it may be related to the failure of its blockbuster products in the respiratory field, budesonide inhalation and digestive system esomeprazole injection, to be successfully included in centralized procurement
.
At present, the whereabouts of most of these resigned executives have been confirmed.
Among them, He Yimin has joined Roche, and others have basically joined local innovative drug companies, such as Baiji and Luoxin
.
Incomplete statistics show that as of August this year, at least eight senior executives of the Chinese business departments of large multinational pharmaceutical companies have left their posts, with an average frequency of one a month; in terms of executives taking on new positions, there are a total of 24 personnel appointments
.
Of course, in addition to multinational companies, the executives of domestic pharmaceutical companies have also changed very frequently this year
.
Among them, it is worth noting that in the context of the departure of domestic and foreign pharmaceutical companies, the exchange of talents between multinational pharmaceutical companies and local innovative drug companies is becoming more and more frequent
.
For example, Liu Yan (Lily), vice president of BeiGene and head of marketing in Greater China, will resign.
According to industry sources, from July 1, he will join Genetron Health as Chief Commercial Officer (CCO) and will be fully responsible for the tumor diagnosis business.
;Jingyan Zhu, former head of the lymphoma business unit of Janssen's HIPO division, joined BeiGene as head of the hematology and oncology division; John P.
Gargiulo, president and CEO of Daiichi Sankyo North America, will join Ascletis after his departure Chief Commercial Officer.
.
.
From the above point of view, the transfer of talents between multinational pharmaceutical companies and domestic and foreign pharmaceutical companies has become the norm
.
The industry predicts that in the future, the flow of talents in the pharmaceutical arena will become more and more frequent, and the competition for talents between multinational pharmaceutical companies and local pharmaceutical companies will continue to intensify
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
